Children's Hospital of Philadelphia
Philadelphia, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Neuroblastoma
FollowWhat is new in Neuroblastoma research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- 18F-DOPAPhase 3 · NCT04706910
- Autologous Hematopoietic Stem Cell TransplantationPhase 3 · NCT03126916
- Biopsy ProcedurePhase 3 · NCT02176967 · NCT03155620
- Biospecimen CollectionPhase 3 · NCT03155620 · NCT07819838 · NCT03210714 · NCT04385277 · NCT04851119 · NCT03213704 · NCT06172296 · NCT03126916 · NCT03213652
- Bone Marrow AspirationPhase 3 · NCT02176967 · NCT07437963 · NCT07819838 · NCT04385277 · NCT06172296
- Bone Marrow Aspiration and BiopsyPhase 3 · NCT03155620 · NCT03210714 · NCT03213704 · NCT03126916 · NCT03213652
- Bone Marrow BiopsyPhase 3 · NCT02176967 · NCT07437963 · NCT07819838 · NCT04385277 · NCT06172296
- BusulfanPhase 3 · NCT05303727 · NCT04221035 · NCT03126916
- CarboplatinPhase 3 · NCT02176967 · NCT02605421 · NCT06942039 · NCT04221035 · NCT06528496 · NCT06172296 · NCT03126916 · NCT04947501
- CisplatinPhase 3 · NCT06942039 · NCT04221035 · NCT06172296 · NCT03126916
- Computed TomographyPhase 3 · NCT04320888 · NCT02176967 · NCT07437963 · NCT03155620 · NCT03210714 · NCT04385277 · NCT03213704 · NCT06172296 · NCT04040088 · NCT03126916 · NCT03213652
- CyclophosphamidPhase 3 · NCT04221035
- CyclophosphamidePhase 3 · NCT04897321 · NCT02176967 · NCT07358260 · NCT07437963 · NCT02605421 · NCT01953900 · NCT06942039 · NCT07502287 · NCT02574728 · NCT04106219 · NCT05296564 · NCT01804634 · NCT07087002 · NCT06172296 · NCT03126916 · NCT04947501 · NCT02298348 · NCT03721068
- DacarbazinePhase 3 · NCT04221035
- Dexrazoxane HydrochloridePhase 3 · NCT03126916
- DinutuximabPhase 3 · NCT07437963 · NCT04211675 · NCT04385277 · NCT03794349 · NCT07261241 · NCT01711554 · NCT06172296 · NCT03126916 · NCT06450041 · NCT02573896
- Dinutuximab betaPhase 3 · NCT07334301 · NCT06485947 · NCT05754684 · NCT04221035 · NCT07688252
- Dinutuximab beta, temozolomide, irinotecan, autologous NK cellPhase 3 · NCT07375563
- DoxorubicinPhase 3 · NCT04221035 · NCT06528496 · NCT06172296 · NCT04947501
- Doxorubicin HydrochloridePhase 3 · NCT02176967 · NCT03126916
- Echocardiography TestPhase 3 · NCT07437963 · NCT06172296 · NCT03126916
- EtoposidePhase 3 · NCT02176967 · NCT02605421 · NCT06942039 · NCT02574728 · NCT04221035 · NCT06528496 · NCT06172296 · NCT04947501
- etoposide phosphatePhase 3 · NCT06942039 · NCT03126916
- External Beam Radiation TherapyPhase 3 · NCT03126916
- FDG-Positron Emission Tomography and Computed Tomography ScanPhase 3 · NCT06172296
- Furosemide InjectionPhase 3 · NCT04706910
- Hematopoietic Cell TransplantationPhase 3 · NCT06172296
- IfosfamidePhase 3 · NCT04221035 · NCT06528496 · NCT04947501
- Iobenguane I-123Phase 3 · NCT04385277 · NCT03126916
- Iobenguane I-131Phase 3 · NCT03126916
- IrinotecanPhase 3 · NCT06541262 · NCT07027748 · NCT04211675 · NCT03189706 · NCT04385277 · NCT04221035 · NCT06528496 · NCT06172296 · NCT06450041 · NCT07085338 · NCT06013618
- irinotecan, temozolomide, dinutuximab beta, NK-cell productPhase 3 · NCT07375563
- ISOtretinoinPhase 3 · NCT06942039 · NCT04385277 · NCT01711554 · NCT06172296 · NCT03126916
- LeukapheresisPhase 3 · NCT06172296
- LorlatinibPhase 3 · NCT03126916
- Magnetic Resonance ImagingPhase 3 · NCT04320888 · NCT02176967 · NCT07437963 · NCT03155620 · NCT03210714 · NCT04385277 · NCT03213704 · NCT06172296 · NCT03126916 · NCT03213652
- MelphalanPhase 3 · NCT02605421 · NCT05303727 · NCT01804634 · NCT04221035 · NCT06172296
- Melphalan HydrochloridePhase 3 · NCT03126916
- monoclonal antibodies GD2Phase 3 · NCT06071897
- Multigated Acquisition ScanPhase 3 · NCT07437963 · NCT04385277 · NCT06172296 · NCT03126916
- Positron Emission TomographyPhase 3 · NCT04320888 · NCT03155620 · NCT03210714 · NCT04040088 · NCT03126916 · NCT03213652
- Radiation TherapyPhase 3 · NCT06528496 · NCT06172296
- Radionuclide ImagingPhase 3 · NCT04320888 · NCT03155620 · NCT03210714 · NCT03213704 · NCT06172296 · NCT03213652
- RadiotherapyPhase 3 · NCT04221035
- SargramostimPhase 3 · NCT07437963 · NCT04211675 · NCT04385277 · NCT03794349 · NCT06528496 · NCT03126916 · NCT07085338
- TemozolomidePhase 3 · NCT04901702 · NCT06541262 · NCT06942039 · NCT07027748 · NCT06995872 · NCT04211675 · NCT03189706 · NCT04385277 · NCT03794349 · NCT06528496 · NCT06172296 · NCT06450041 · NCT07085338 · NCT06013618 · NCT04337177
- Temozolomide 100 MGPhase 3 · NCT04221035
- Therapeutic Conventional SurgeryPhase 3 · NCT03126916
- ThiotepaPhase 3 · NCT02605421 · NCT06942039 · NCT05303727 · NCT04221035 · NCT06172296 · NCT03126916
- TopotecanPhase 3 · NCT07334301 · NCT07437963 · NCT05303727 · NCT04106219 · NCT06528496 · NCT06172296 · NCT04947501 · NCT02298348
- Topotecan HydrochloridePhase 3 · NCT03126916
- Tumor ResectionPhase 3 · NCT06172296
- UltrasoundPhase 3 · NCT02176967
- VincristinePhase 3 · NCT06541262 · NCT06942039 · NCT06721689 · NCT04221035 · NCT06528496 · NCT06172296 · NCT04947501
- Vincristine SulfatePhase 3 · NCT03126916
- VindesinePhase 3 · NCT04221035
- AlectinibPhase 2/3 · NCT05770037
- CapmatinibPhase 2/3 · NCT06988475
- hu1418K322A + Temozolomide + IrinotecanPhase 2/3 · NCT07549321
- 177Lu-DOTATATEPhase 2 · NCT04903899
- 18F-MFBG PET/CT imagingPhase 2 · NCT07111117
- Anti Thymocyte GlobulinPhase 2 · NCT05303727
- Arsenic trioxidePhase 2 · NCT06933394 · NCT03503864
- Autologous Stem Cell InfusionPhase 2 · NCT02605421
- Bone ScanPhase 2 · NCT03155620 · NCT03210714 · NCT03213704 · NCT03213652
- CabozantinibPhase 2 · NCT05135975
- CelecoxibPhase 2 · NCT06942039 · NCT02574728
- CeritinibPhase 2 · NCT02559778
- ChemotherapyPhase 2 · NCT06933394
- Chidamide Combined with Dinutuximab Beta, Irinotecan, and TemozolomidePhase 2 · NCT07318831
- CIML-NK CellsPhase 2 · NCT07635056
- Cyclophosphamide injectionPhase 2 · NCT05303727
- CyclosporinePhase 2 · NCT05303727
- CytoxanPhase 2 · NCT01192555 · NCT01822652 · NCT06528496
- DANYELZAPhase 2 · NCT06528496
- dasatinibPhase 2 · NCT02559778
- DFMOPhase 2 · NCT02559778
- Difluoromethylornithine (DFMO)Phase 2 · NCT02679144
- Dinutuximab with ChemotherapyPhase 2 · NCT05421897
- EflornithinePhase 2 · NCT04301843
- Eflornithine HydrochloridePhase 2 · NCT03794349
- EnasidenibPhase 2 · NCT06176989
- EnsartinibPhase 2 · NCT03155620 · NCT03213652
- ErdafitinibPhase 2 · NCT03155620 · NCT03210714
- FDG-Positron Emission TomographyPhase 2 · NCT07437963 · NCT04385277
- FludarabinePhase 2 · NCT04897321 · NCT07358260 · NCT01953900 · NCT07502287 · NCT05303727 · NCT01804634 · NCT07087002 · NCT03721068
- Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)Phase 2 · NCT06255210
- GM-CSFPhase 2 · NCT04936529 · NCT03189706 · NCT06450041 · NCT06013618
- GM-CSF + NaxitamabPhase 2 · NCT03363373
- GM-CSF with combination regimenPhase 2 · NCT06013618
- Granulocyte colony stimulating factorPhase 2 · NCT02605421
- Granulocyte-Macrophage Colony-Stimulating FactorPhase 2 · NCT05754684
- hu14.18K322APhase 2 · NCT07085338
- Interleukin-2Phase 2 · NCT05754684
- iobenguane I 131Phase 2 · NCT00107289
- Irinotecan HydrochloridePhase 2 · NCT06995872 · NCT03794349
- IvosidenibPhase 2 · NCT03155620 · NCT04195555
- Larotrectinib SulfatePhase 2 · NCT03155620 · NCT03213704
- Liposomal Irinotecan, Vincristine, Temozolomide, and Optional AnlotinibPhase 2 · NCT07444918
- low dose total body irradiationPhase 2 · NCT01804634
- MAPK inhibitorsPhase 2 · NCT06933394
- MethioninePhase 2 · NCT00840047
- MethotrexatePhase 2 · NCT05303727
- MIBGPhase 2 · NCT02378428
- Mutation Carrier ScreeningPhase 2 · NCT03155620
- Mycophenolate MofetilPhase 2 · NCT05303727
- N803Phase 2 · NCT07085338
- Natural killer cellPhase 2 · NCT05754684
- NaxitamabPhase 2 · NCT05489887 · NCT07027748 · NCT06540963 · NCT07537400 · NCT05754684
- Naxitamab in combination therapyPhase 2 · NCT06013618
- Naxitamab monotherapyPhase 2 · NCT06013618
- NivolumabPhase 2 · NCT07100704 · NCT02914405 · NCT06638931
- OlaparibPhase 2 · NCT03155620
- OPT-821Phase 2 · NCT04936529
- OPT-821 (QS-21)Phase 2 · NCT06057948
- PalbociclibPhase 2 · NCT03155620
- Radiation: 131I-MIBGPhase 2 · NCT07261241
- Radiopharmaceutical 68Ga-DOTATATEPhase 2 · NCT04559217
- SamotolisibPhase 2 · NCT03155620
- SelpercatinibPhase 2 · NCT04320888 · NCT03155620
- Selumetinib SulfatePhase 2 · NCT03155620
- SintilimabPhase 2 · NCT06013618
- SirolimusPhase 2 · NCT02574728
- sorafenibPhase 2 · NCT02559778 · NCT02298348
- SpironolactonePhase 2 · NCT05754684
- TacrolimusPhase 2 · NCT05303727 · NCT01804634
- TazemetostatPhase 2 · NCT03155620
- TipifarnibPhase 2 · NCT04284774 · NCT03155620 · NCT06540963
- UlixertinibPhase 2 · NCT03698994 · NCT03155620
- Universal Donor (UD) TGFβi NK CellsPhase 2 · NCT06450041
- VemurafenibPhase 2 · NCT03155620
- VorinostatPhase 2 · NCT04308330 · NCT02559778 · NCT07261241
- X-Ray ImagingPhase 2 · NCT04320888 · NCT03155620 · NCT07819838 · NCT03210714 · NCT04851119 · NCT03213704 · NCT03213652
- ZanzalintinibPhase 2 · NCT07527169
- Afamitresgene autoleucelPhase 1/2 · NCT05642455
- AldesleukinPhase 1/2 · NCT05296564
- AMXT 1501 DicapratePhase 1/2 · NCT06465199
- anti-GD2-800CWPhase 1/2 · NCT07399821
- APG-115Phase 1/2 · NCT05701306
- APG-2575Phase 1/2 · NCT05701306
- Autologous hALK.CAR T cellsPhase 1/2 · NCT06803875
- autologous NK cell plus GD2 antibodyPhase 1/2 · NCT06948994
- BevacizumabPhase 1/2 · NCT07334301
- CART therapyPhase 1/2 · NCT06836505
- CYCLOPHOSPHAMIDE and FLUDARABINPhase 1/2 · NCT05296564
- cytokine induced killer cellsPhase 1/2 · NCT01868490
- DaraxonrasibPhase 1/2 · NCT07819838
- Diagnostic Imaging TestingPhase 1/2 · NCT07819838
- Dual X-ray AbsorptiometryPhase 1/2 · NCT04851119
- EB-DTNB-NKPhase 1/2 · NCT07502287
- Eflornithine (DFMO)Phase 1/2 · NCT06465199
- ELI-002 7PPhase 1/2 · NCT05726864
- EntrectinibPhase 1/2 · NCT02650401
- GD2-CART01Phase 1/2 · NCT03373097
- GD2, PSMA and CD276 CAR-T cellsPhase 1/2 · NCT04637503
- HBI 0201-ESO TCRTPhase 1/2 · NCT05296564
- Hu3F8 With GM-CSFPhase 1/2 · NCT01757626
- IberdomidePhase 1/2 · NCT07437963
- Irinotecan (drug)Phase 1/2 · NCT07334301
- Miltenyi CliniMACS Prodigy ® systemPhase 1/2 · NCT06625190
- Natural Killer CellsPhase 1/2 · NCT04211675
- Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cellsPhase 1/2 · NCT01192555
- Nuclear Radiology Imaging ProcedurePhase 1/2 · NCT07437963
- Olaparib; 177Lu-DOTATATEPhase 1/2 · NCT06607692
- OnivydePhase 1/2 · NCT04901702
- PEEL-224Phase 1/2 · NCT06721689
- SilmitasertibPhase 1/2 · NCT06541262
- TalazoparibPhase 1/2 · NCT04901702
- TegavivintPhase 1/2 · NCT04851119
- Temozolomide (TMZ)Phase 1/2 · NCT07334301 · NCT06721689
- Zilovertamab vedotinPhase 1/2 · NCT06395103
- Zoledronic acidPhase 1/2 · NCT06625190
- [203Pb]VMT-alpha-NETPhase 1 · NCT06479811
- [212Pb]VMT-alpha-NETPhase 1 · NCT06479811
- 68Ga-DotatatePhase 1 · NCT05069220 · NCT06479811
- ADCT-701Phase 1 · NCT06041516
- Allogenic NK cells infusionPhase 1 · NCT06674265
- AvutometinibPhase 1 · NCT06104488
- B7-H3 CAR T cellsPhase 1 · NCT04897321
- B7-H3.CD28Z.CARTPhase 1 · NCT07358260
- B7-H3CART Dose (Intravenous)Phase 1 · NCT06500819
- Becotatug VedotinPhase 1 · NCT07584499
- Bevacizumab (Avastin)Phase 1 · NCT07897968
- BiologicalPhase 1 · NCT05608148
- C7R-GD2.CART cellsPhase 1 · NCT03635632
- Ch14.18/CHOPhase 1 · NCT02914405
- Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)Phase 1 · NCT05272371
- chemotherapy treatment called GPOHPhase 1 · NCT06485947
- chemotherapy treatment called rapid COJECPhase 1 · NCT06485947
- Chimeric Antigen Receptor (CAR) Therapy InfusionPhase 1 · NCT07897968
- Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)Phase 1 · NCT06751134
- CLR 131Phase 1 · NCT03478462
- DinituximabPhase 1 · NCT06995872
- Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and ZoledronatePhase 1 · NCT05400603
- FludaraPhase 1 · NCT01822652
- GD2 CAR T cellsPhase 1 · NCT05990751
- GD2 T cellsPhase 1 · NCT01953900
- GINAKIT CellsPhase 1 · NCT03294954
- GINAKIT cells + EtanerceptPhase 1 · NCT03294954
- GPC2 CAR T cellsPhase 1 · NCT05650749
- GPC2-CAR T cellsPhase 1 · NCT07087002
- i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cellsPhase 1 · NCT07211737
- iC9-GD2 T cellsPhase 1 · NCT01822652
- iC9-GD2 T Cells - freshPhase 1 · NCT01822652
- iC9-GD2 T Cells - frozenPhase 1 · NCT01822652
- iC9.GD2.CAR.IL-15 T-cellsPhase 1 · NCT03721068
- Induction chemotherapyPhase 1 · NCT07688252
- KeytrudaPhase 1 · NCT01822652
- LenalidomidePhase 1 · NCT01711554 · NCT02573896
- LY3295668 ErbuminePhase 1 · NCT04106219
- MESNAPhase 1 · NCT04897321 · NCT06942039 · NCT04947501
- MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamidePhase 1 · NCT02013336
- NK CellsPhase 1 · NCT02573896
- Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)Phase 1 · NCT02311621
- Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)Phase 1 · NCT02311621
- Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)Phase 1 · NCT02311621
- PembrolizumabPhase 1 · NCT04483778
- PHOX2B PC-CAR T CellsPhase 1 · NCT07007117
- rhIL-15Phase 1 · NCT06995872
- Sargramostim granulocyte-macrophage colony stimulating factorPhase 1 · NCT07027748
- second generation 4-1BBζ B7H3-EGFRt-DHFRPhase 1 · NCT04483778
- second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tGPhase 1 · NCT04483778
- second generation 4-1BBζ EGFR806-EGFRtPhase 1 · NCT03618381
- second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tGPhase 1 · NCT03618381
- Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cellsPhase 1 · NCT07172958
- T cell injection targeting B7-H3 chimeric antigen receptorPhase 1 · NCT05562024
- TCRαβ+/CD19+ depleted Haploidentical HSCTPhase 1 · NCT02508038
- Therapeutic Inducers of Natural Killer Killing (ThINKK)Phase 1 · NCT07518654
- Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)Phase 1 · NCT04837547
- umbilical cord blood NK cellsPhase 1 · NCT06631391
- VAL-413Phase 1 · NCT04337177
- VZV vaccinePhase 1 · NCT01953900
- ZoledronatePhase 1 · NCT02508038
- [211At]MABGEarly phase 1 · NCT07767630
- 18F-DAEarly phase 1 · NCT03541720
- 18F-MFBGEarly phase 1 · NCT05069220
- Cytarabine ITEarly phase 1 · NCT06942039
- EliglustatEarly phase 1 · NCT07090538
- FilgrastimEarly phase 1 · NCT06942039
- Gallium Ga 68-DOTATATEEarly phase 1 · NCT04040088
- GD2-CAR-T cellEarly phase 1 · NCT06684639
- Hu3F8Early phase 1 · NCT03189706
- hydrocortisoneEarly phase 1 · NCT06942039
- IR-101Early phase 1 · NCT07067346
- TamoxifenEarly phase 1 · NCT06942039
- Topotecan ITEarly phase 1 · NCT06942039
Closest to patients
- Induction Chemoimmunotherapy for Patients With High-risk NeuroblastomaInduction Chemoimmunotherapy for Patients With High-risk NeuroblastomaResearch Institute of Pediatric Hematology, Oncology and Immunology · Moscow, RussiaPhase 3Results expected 2026
- Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk NeuroblastomaResponse and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk NeuroblastomaUniversity Medical Center of Southern Nevada · Las Vegas, United States + 221 more hospitalsPhase 3Results expected 2026
- High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Universitair Medisch Centrum Groningen · Groningen, Netherlands + 207 more hospitalsPhase 3Results expected 2026
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Cyclodextrin-enabled δ-Tocotrienol for Treating Stress and Memory Dysfunction: Molecular Insights, Biotechnological Applications and Biomanufacturing Implications.
Cyclodextrin-enabled δ-Tocotrienol for Treating Stress and Memory Dysfunction: Molecular Insights, Biotechnological Applications and Biomanufacturing Implications.
Annals of neurosciences
PubMed · PMID 42865782Publication
Anticancer and Bactericidal Activity of Manganese Ferrite Nanoparticles Synthesised by Using Allicin Extract.
Anticancer and Bactericidal Activity of Manganese Ferrite Nanoparticles Synthesised by Using Allicin Extract.
Asian Pacific journal of cancer prevention : APJCP
PubMed · PMID 42808392Publication
Protective effects of Lactobacillus acidophilus LM1060 on LPS/H2O2-induced cytotoxicity in SK-N-SH cells and scopolamine-induced memory impairment in mice.
Protective effects of Lactobacillus acidophilus LM1060 on LPS/H2O2-induced cytotoxicity in SK-N-SH cells and scopolamine-induced memory impairment in mice.
Nutrition research and practice
PubMed · PMID 42889433
Find fellow researchers
Groups with active Neuroblastoma work.
Capital Medical University
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
St. Jude Children's Research Hospital
Memphis, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Princess Máxima Center
Utrecht, Netherlands
Team details appear once the team leader joins.
Is this your team? Claim it
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Pennsylvania
Philadelphia, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Istituto Giannina Gaslini
Genoa, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
National Cancer Institute
Bethesda, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Centre National de la Recherche Scientifique
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Institut Curie
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Beijing Friendship Hospital
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it